Social Media Wiki Digital Data Bank

One More Reason Pharma Needs Product Reviews

A few weeks back, I wrote a post about why pharma and healthcare companies need to consider adding product reviews to their sites. For those of you who didn’t read that article and thus are completely up in arms that I would suggest this, please take a look at my original article before you decide. You’ll see that I’m readily acknowledging that adding ratings and reviews to a brand site wouldn’t be simple and isn’t without its regulatory risks, but I am trying to argue that the benefits just might outweigh the risks.

Here was the main reason from this earlier post why I think product reviews are important for pharma (if you already read the post, you can skip this):

So, how is adding product reviews going to help you sell more of your product? One of the first things they teach you in sales and marketing is that a customer saying “no” to your sales pitch isn’t necessarily a bad thing. The reason why is because, with some questions, you can figure out why they aren’t interested, and deal with these issues. But going through all of this effort is very expensive. Just look at the budgets pharma companies allocate for field sales teams if you don’t agree. When it comes to pharma, or any industry, keeping your current customers is always cheaper than finding new ones. The people writing reviews on iGuard, for example, are already on your product. You’ve spent money on DTC TV, iMedia, the sales team, print ads, and a thousand other tactics, but now you’re about to lose them. Unless you don’t.

When comments are on a 3rd party site like iGuard instead of your own, you can’t be involved in the conversation. Imagine instead that they were on your site. This would allow you to do two things. Since you would require people to register to leave a comment (and you would), they also would provide their contact information. You can ask them if they’d like someone to contact them about their issue when they sign up. In this case, when someone posts a review saying they are having a certain side effect, you can do something to keep them on your product. Chances are that if this patient doesn’t get an answer, they’ll stop your treatment. So, you can have a nurse or other professional call and talk about the person’s issue. You can even go so far as to contact with the person’s doctor (with his or her permission) and explain the problem. The doctor can then follow up with appropriate actions like dosage adjustments, side effect management, or, where necessary, switching the patient to something different.

Think for a minute how this would be perceived by the medical community and patients. Wouldn’t doctors like to know when their patients are having a problem with their medication?

So if that’s not a compelling enough reason, let me give you one more. Search engine optimization. Before you go ahead and say that search isn’t important for healthcare or that it’s currently being done well in this industry, think again. Read my article about the state of search optimization for the five biggest selling pharma brands. The quick and dirty summary is that for major keywords, most pharma sites don’t make it to the first handful of pages on Google search results, this means that virtually no one is finding their sites through search…a big missed opportunity.

One of the big reasons for this is because of the language that us healthcare marketers (myself included) like to use. We say “treatment” instead of “remedy,” for example, but “remedy” is searched far more often because that’s how our customers talk. It’s actually searched for twice as often when it comes to heartburn (for example) according to Google’s data.

remedy versus treatment Google

Because we say “treatment” we also write our website pages using “treatment.” This means that we never use the word “remedy” so Google never puts our sites in search results for the word “remedy.” But that’s how our customer’s are searching. One more reason that knowing these types of terms is important is because oftentimes the websites that “own” these “remedy” search results aren’t perhaps the best source of medical information. Let’s use the heartburn example again. When I search for “heartburn treatment” on Google, the number one result is a page on USA Today’s website. Not exactly the American College of Gastroenterology, but still reputable. However, when I search for “heartburn remedy” on Google, it’s a different story. I get a website that could at best be called a homemade site. Here’s a quick preview of the site:

homemade heartburn

I’m not knocking homemade sites, nor am I concerned about the look of this site, but rather the content. The first heartburn “remedy” you see on the page is this:

“Sherbert[sic] . any sherbert [sic] dip will do. Ive tried everything over the counter medication and nuthing [sic] works, maybe gives relief for a couple of hours but thats [sic] it. ONLY SHERBERT ITS [sic] Excellent TRY IT!”

Wow. I know that this recommended heartburn remedy is having the opposite effect on a product manager somewhere, but know that this is what your customers are seeing when they search for “heartburn remedy.” PS: the word is SHERBET, not SERBERT. You can do this same experiment with ANY disease and you’ll get the same result.

So what does this have to do with ratings and reviews? I’ve already said that those of us in healthcare marketing including our medical teams, speak in, well, medical language. That’s why we say “treatment” instead of “remedy.” It’s hard for us to think of it any differently, so it would be hard to write our content using any different language. Yes, we’ve done a really good job of taking our content and making it easy to understand including our inscrutable prescribing information. However, as we simplify, we often don’t use natural language. In this case, natural language means the language and terms that your customers are using to describe their condition and its treatment. It’s difficult to research the precise language that people use in these cases and to incorporate it into the content on your site. But there’s a simple way to fix this. Reviews.

By letting people write reviews that you then include on your site, you automatically generate the natural language and terms that your customers use to conduct searches. That is, they won’t write: “Drug X is the best heartburn treatment I’ve ever tried.” They’ll write: “Drug X is the best heartburn remedy I’ve ever tried.” This is an oversimplified example, of course, but you get the idea. Over time, your site will become optimized for the natural language searches that your customers are using. And the best part? You didn’t have to pay a dime for an agency to come up with the copy. You didn’t have to spend time researching how customers talk about your product (and pay a fortune). Your customers do it for you.

Of course, it’s not that simple. Allowing reviews on your site creates some other challenges particularly around adverse event reporting. But the question then becomes, is the value of owning natural language search terms and the increased traffic that comes to your site from people seeking solutions worth it? It’s easy for me to say yes, but can it be easy for you as well? Here’s my take from my previous reviews posting:

Yes, you will have to deal with adverse events if you go with product reviews. With a simple process, you can moderate every comment and deal with it appropriately. It’s ironic that pharma companies always cite this issue of adverse events when it comes to getting feedback from patients particularly when discussions about social media come up. However, at the same time, more and more companies are voluntarily adding links (which I bet will be required soon enough) to the FDA website and a phone number encouraging people to report adverse events directly to the FDA. This tells me that pharma companies aren’t necessarily afraid of what they might hear, but rather that they simply don’t want to deal with the information. That is, they don’t want to create a process to deal with it. But all these companies already have processes in place for adverse event reporting. An electronic version would flow quite simply into this. Also, keep in mind that you aren’t required to post every comment or review on your site. Those that are inappropriate (not just negative, but contain rants or foul language, for example) can be taken out. You simply need to ensure that you are transparent about your policy on how you moderate comments and which you post and which you don’t.

Again, not saying it’s simple or easy, but I am challenging you to ask the question: does the benefit outweigh the risk?

4 Technologies That Are Killing the URL

A few weeks ago I submitted an article to iMedia Connection that I originally wrote for this blog. However, I couldn’t really figure out a solid pharma and/or healthcare angle, so I sent it to them to see if they were interested. They were. As you know, I just started writing a blog for iMedia Connection. I’m including stories there that aren’t really healthcare specific, but I’m also including a link from this blog because I think they are still interesting for most of Dose of Digital’s readers. (PS: Thanks to all of you who read the Twitter article I wrote. It’s still the most popular blog post on iMedia.)

Apparently, the folks at iMedia Connection liked my latest article, as they’ve made it the featured cover story. Check it out:

imediaclipcover

To read the full article, please check it out: 4 Technologies That Are Killing the URL. If you really want to see my mugshot on iMedia Connection’s cover, then go to their homepage: http://www.imediaconnection.com. It’ll only be on there for a few days though. After that, you’ll have to take my word for it.

Here are the article highlights:

Article Highlights:

  • Search engines and browsers elevate solid search marketing strategies over mere URLs
  • URL shortening services negate the branding of your web address
  • QR codes and image recognition technologies represent the URL killers of the future

More pharma/healthcare blog posts later this week, but wanted to share one more non-healthcare post with you.

Greetings from the Business Development Institute Conference

Yesterday, I had the chance to speak at the Business Development Institute’s Social Communications & Healthcare Case Studies and Roundtables Conference. It was a well-done conference with about 350 people in attendance, which is a pretty big number these days. I also got to meet in person some of my Twitter friends, which was great.

Speaking of Twitter, there was quite a bit of participation during the conference and you can run through the entire stream. You can search for #bdi or review it all in real time here.

My talk was called Healthcare & Social Media: Know the Rules. You can listen to my talk using the player below, but first, you can download a PDF version of the presentation so you can follow along (though you’ll have to guess a bit when to flip to the next slide): Healthcare and Social Media...Know the Rules. My talk starts around the 68:08 minute mark if you want to jump to it. For the record, I did not provide this introduction to Steve, the host of the conference. Seriously. [If you're viewing this in an RSS reader or email client, you'll most likely have to click through to the post for the player to work.]

The version you can download above is exactly what I presented in New York. However, you probably noticed that there aren’t many words on the slides (a pet peeve of mine). What this means is that without my “script” these probably don’t make that much sense. So, here’s a PDF of a fully annotated version with more details on the slides, a few slides that I had to cut because of time, and my full speaking notes. Here’s the link: Annotated Version of Healthcare and Social Media...Know the Rules

You also might be interested in the Pharma and Healthcare Social Media Wiki, which I mentioned in my talk. It’s where you can find a bunch of examples of other pharma and healthcare companies have ongoing programs in some social media channel.

A few more things while I’ve got you here…

Don’t forget to subscribe, so you don’t miss anything in the future.

Subscribe to the Dose of Digital RSS Feed

I can also send you an email anytime I publish a new white paper. Interested? Fill in the form below. Rest assured that your email will never be sold, rented, or shared with anyone. I hate spam more than you do. If you’re viewing this in an RSS reader or email client, you’ll have to click through to the post for the form to work.


* indicates required

Lastly, be sure to check out the Mini White Paper Series. These are posts on a general issue that can be re-applied to many other situations. For example, my post on The Myth of Adverse Event Reporting covers how pharma can deal with adverse event reports and how often they really occur online. The information in that post can be used in a number of different situations. So, that’s what it takes to be a “Mini White Paper.” And, yes, they’re long. So, here are all the articles that currently feature the Mini White Paper icon:

Mini White Paper

Diagnosis In: Twitter’s Dying a Slow Death

One more post that’s non-pharma/healthcare specific, so I put it on iMedia Connection.

Please check out my latest post: Diagnosis In: Twitter’s Dying a Slow Death

Here’s a little teaser: “Okay, so Twitter may have more than a few months to live, but it’s not going to be around for much longer the way I see it for one simple reason. It’s not because of all the issues with security that have been all over the digital news lately. It’s not because there’s something better. It’s not even because someone’s going to buy Twitter. Twitter has a terminal disease and nothing really can save it. The disease? Spam.”

imedia connection

More Digital Insights (Now with LESS Pharma)

That’s right. I know a little bit more about digital than what’s happening in pharma. Since I know the audience here really likes to tackle pharma and healthcare-specific issues, I haven’t really posted any general digital commentary. I may in the future (let me know your thoughts in the comments), but for now, we’ll stay focused.

Since I do have a bunch to say about digital in other industries, I needed a new venue. The people at iMedia Connection just gave me one. They’ve taken me on as one of their bloggers. If you visit my blog there, you’ll  see some more of my thinking on general digital issues that aren’t directly relevant to pharma. You might just pick up a few things you can use.

As a Dose of Digital reader, you’ll see a few of the posts from here appear on my iMedia blog as well, but mostly it’ll be new content.

So, please check out my first post on iMedia Connection: Do I Know You From Somewhere?

Here’s a little teaser: “Remember business cards? Remember meeting people in the real world? Not the Twittersphere or on LinkedIn, I mean the actual, physical world. Of course, we still meet new contacts in person from time to time, but more and more we “meet” them online. It only makes sense. We spend a lot of our time online searching for information and with that comes the fortunate by-product of finding others with similar interests. I follow you, you follow me. I add you to my connections, you add me. It wasn’t always like this.”

imedia connection

Emerging Media in Healthcare and Pharma White Paper

After my recent post where I shared my white paper on “The Future of Digital Relationship Marketing in Pharma,” many of you inquired if I had any similar papers. You’re in luck. I have one that’s a different topic, but I think related.

This one is called: “Emerging Media in Healthcare and Pharma.”

Here’s a brief summary:

“There are a significant number of emerging media areas that will affect healthcare and pharmaceutical marketing campaigns in the future. Some will have an enormous positive impact on current marketing practices, while others will have devastating negative consequences on these same practices. The good news is that there are alternatives to the way many current campaigns are conducted that leverage the best in consumer understanding, interactive technologies, and solid marketing strategy (all while staying within DDMAC rules).”

I identified eight emerging media trends that about which I think every healthcare and pharma marketer should be aware:

  • Medical Social Networking: Beyond Facebook and MySpace, patients are now connecting with one another online and taking each other’s advice, sometimes over their physician’s advice.
  • Live and (Almost) in Person: YouTube is fine for delivering content, but it is instantly outdated. Consumers want to use video to interact with a real person to get the freshest information all from the comfort of their homes. This includes their doctors.
  • Secure Communications: People will begin to trust more of their confidential information online, but will expect that it be protected through constantly secure channels.
  • Micro-targeting: Targeting consumers has evolved dramatically in the past 10 years to the point where it is possible to find and communicate with a small group of brand supporters in a highly cost effective manner.
  • Instant, Dynamic Content: Online content must now immediately change based on user inputs. Providing the same content for everyone regardless of what they do on your site is a losing proposition.
  • Mobile Grows Up: Typically seen as a marketing platform that could only reach teenagers, older users are beginning to adopt some of the same habits as younger consumers, opening up a range of new promotional options.
  • Managing and Leading Word of Mouth: Tracking down everything that someone says about your brand was impossible without Internet-based technologies. Now brands are expected to track, and where appropriate, join in the conversations that people are having about them.
  • Print Goes Interactive: Print isn’t dead, but it needs to leverage interactive technologies to stay relevant and match consumer behaviors.

If you want more information on each of these trends, then you can download my full white paper on this topic: Emerging Media in Healthcare and Pharma  (767 downloads)

As an added bonus, I want to share a copy of an article I had published in Pharmaceutical Executive last year called “Exercising Your Brand.” This paper outlines these rules healthcare marketers must follow to help ensure a successful digital program. I’ll share the link with you via DM on Twitter if you send this tweet about today’s post (PS: make sure you’re following me, so I can DM you). Deal?

If you want to be informed of any new white papers I publish, just fill out the form below. Your information will only be used for this purpose and will never be shared under any circumstance.

  1. (required)
  2. (valid email required)
 

cforms contact form by delicious:days

Note: Stay tuned for an updated version of this paper in the coming months. Emerging media changes quickly, so it’s difficult to stay current no matter how often you’re updating.

What Pharma Can Learn from the Pizza Guy

Dose of Digital Mini White Paper

I just couldn’t resist this post title after the response I had to my post (both positive and negative) called: What Pharma Can Learn from Pringles. Without going into too much detail, the takeaway message was supposed to be simple. Pharma and healthcare can learn a lot about the approaches other industries take in their marketing. Yes, pharma in particular is heavily regulated and limited in what they can do or say, but too often the best practices of other industries are ignored instead of us figuring out how to apply what worked well elsewhere to what we’re doing in pharma. It’s a big missed opportunity that I’ve been working on fixing for a long time.

So, in keeping with this theme, I wanted to share a concept that we call “The Selfish Consumer.” It was created by our Chief Technology Officer, Michael Wilson, here at Bridge Worldwide. Here’s the basic idea:

“TiVo, iPod, and blogging have something more in common than the right technology at the right time. They provide the same old media in new and interesting ways. This not only changes consumer behavior, but forever shifts consumer attitude. Greedy for content and equipped with almost magical abilities to control media delivery, we have armed a very intelligent consumer.”

View Michael’s presentation on “The Selfish Consumer” here:

We’re not saying that your consumers are “selfish” in a bad way, but that digital technologies simply make it easy for them to be when it comes to digital content. As marketers, we need to accept this as the new reality. But what does it mean for us? There are actually three implications, which are all closely related:

  • Quality: We need to ensure that we’re creating great content and giving access to it in ways “The Selfish Consumer” demands
  • Competition: Everything online is potentially a competitor when we understand that we’re all competing for the same consumers’ time and attention
  • Expectation: What “The Selfish Consumer” gets from one industry when it comes to digital, he expects from every other

I’ve done a couple of presentations and blog posts about the first two: quality and competition. The most recent was my presentation “If You Build It, They Will Come…Or Will They?“, which addresses “Competition,” you can find on SlideShare. So, today, I’m going to address “Expectation.”

“Expectation” is a pretty simple concept. If a customer is used to getting a certain service from one company, he expects it from all that company’s competitors. This is why new innovations and special offers get duplicated so quickly and so readily. This happens within industries and it’s very common. However, it’s rare that a special offer from one industry gets carried over to another. Just because Subway is offering buy one, get one free sandwiches doesn’t mean the Hilton down the street is offering buy one, get one free rooms. When it comes to digital technologies, it’s a whole different story.

If one industry offers a certain digital technology, then “The Selfish Consumer” expects every industry to offer it. This concept (and example) was first explained to me by my colleague Bob Gilbreath, Chief Marketing Strategist here at Bridge Worldwide. What Bob pointed out is that if people now can track their package online thanks to FedEx and UPS, they expect this same thing in other industries including those industries that have nothing to do with packages. So, here’s what “The Selfish Consumer” says: “If I can track my package online, then I should be able to track my pizza online too.” And, thanks to Domino’s, now you can.

Dominos Pizza Tracker

Yikes. If you’re bringing something to “The Selfish Consumer,” there had better be a way for them to track it. That’s now the standard…the expectation. What does this all mean for pharma? It means that pharma needs to look at what digital technologies and tools its consumers are getting from other industries. Once you know what they are, take a look and see which might translate well to pharma. Need a hand?

Nike+

If I can track my exercise progress thanks to my shoe company, I should be able to do the same with my healthcare company. Of course, you can. There are quite a few trackers out there, so this is a perfect example of one industry’s lead moving over to pharma. No, Nike+ didn’t create the first health tracker, but neither did a pharma company (bonus points for anyone who knows who did). Nike+ is a health tracker in the end, so that’s not a big leap. But what’s next? Here are a few common digital tools and technologies that consumers get from other industries and might start demanding from pharma:

  • Product reviews — I’ve already talked about product reviews a lot (with more to come later this week). Consumers get them everywhere online now and use them to make purchase decisions on everything from very low to very high involvement items.
  • Online customer service –I wrote about this a while back in a post called “Providing Meaningful Customer Service in Healthcare.” According to a recent Manhattan Research study, “More than three-quarters of ePharma Consumers report that they “expect” online customer service from a pharmaceutical company.” EPharma Consumers are “those who use the Internet to research prescription drug information. In past five years alone this group has tripled to about 95 million U.S. adults.” Why? Because they get online customer service from every company they interact with online from shoes to books to vacations. Everything you can buy or think about buying has some form of online customer service. Why not pharma?
  • Privacy — Nothing is more private than someone’s health. Yet, we pharma marketers ask people to tell us an awful lot about themselves before we give them something of value. More and more other marketers are moving away from this and allowing people to register with limited or no information. They use technologies like OpenID, so that visitors don’t have to register (and give out more personal information) for yet another site in order to get access to a website. That means you don’t even have to share an email address to get access. Most marketers are also very careful with the information they capture online. For instance, if you’re not going to use someone’s home mailing address for a certain promotion, then you really shouldn’t be asking for it for two reasons. Number one, asking for less increases the chance that someone will complete the enrollment process. And number two, it’s none of your business. Yes, you might say that you’re going to use it later for something different. Well, that person didn’t register for “something different,” they registered for one particular thing. They gave you their information only for that purpose (PS: using fancy opt in choices with pre-checked boxes or double-negative language doesn’t really entitle you to use information later).
  • Aggregation and deferment – Two related ideas here. First, there are many sites out there that simply pull together all the content related to a specific topic and put it one place for you to review at your leisure. They are called aggregators (see: Netvibes or Pageflakes for an example). Pharma companies might just find that using aggregators is the simplest way to create a disease awareness portal that works the way “The Selfish Consumer” expects. The folks at S&R Communications Group just had a great post on this very topic. Today’s consumers can set up an iGoogle page with everything they want, why not every new piece of information about their disease on one page? Aggregators would pull content from the best sources, the leading experts, bringing together the best of the best information instead of relying on a single source (i.e., you).  Deferment is related to aggregation because it too involves turning to outside experts in the areas where you are not the expert. In the case of a pharma company, you might be the expert in high cholesterol since you make one (or more) products to treat this condition. A key part of the treatment for high cholesterol is diet and exercise management. However, a pharma company is not an expert in diet or exercise. There are plenty of people who are though and whose names and experience are far more credible than yours in this area. For example, perhaps you turn to the people from Weight Watchers for the diet portion of your content. They are recognized as experts in this area. This works for two reasons. First, it frees you up to focus on what you know best: high cholesterol. Second, it also tells your consumers that you have their best interest in mind. You’re not trying to do everything yourself, you know when someone might know more than you. You are essentially providing your consumers with referrals to other experts. This is the “Enlist” part of my four tenets for best in class digital strategy in healthcare.

While it may seem really challenging and a ton of extra work to connect with today’s “Selfish Consumer,” it’s worth the effort. First, and most basic, this is what your customers are demanding. If you remotely subscribe to the notion that “the customer is always right,” then you should get on board with this as well. Second, the most “selfish” of consumers aren’t selfish at all. In fact, they share…a lot. They share things they like and things they don’t. So, if you do your job with them, they’ll help spread the word for you about your product and company. If you don’t do your job, then they’ll still spread the word, but you won’t like what they have to say.

Older Posts »